Clinics in Laboratory Medicine 1992: Vol 12 Index

27 Pages·1992·4.9 MB·English

CUMULATIVE INDEX 1992
Volume 12
March LABORATORY IMMUNOLOGY I, pages 1-162
June LABORATORY IMMUNOLOGY II, pages 163-392
September REPRODUCTIVE MEDICINE AND THE CLINICAL
LABORATORY, 393-654
‘December SELECTED TOPICS IN TRANSFUSION MEDICINE,
pages 655. 826
Note: Page numbers of article titles are in boldface type
ABO blood groups, determination of, for Alanyl tRNA synthetase, antibodies to, in
transfusion, 686-689 polymyositis, 11
hemolytic disease of newborn and, 556- Albumin, fetal. See Alpha-fetoprotein.
559 in hemapheresis, 591, 593, 598-599
in parentage analysis, 621-625 Allele-specific oligonucleotide probes, in
Abortion, immunologic mechanisms in, Tay-Sachs disease assessment, 472
557, 559 Alloantibody analysis, in hemolytic
Accident reports, in transfusion medicine, disease of newborn, 561-562
837 Allograft rejection. See Transplantation,
Acetylcholinesterase, measurement of, rejection markers in.
neural tube defects and, 485, 489 Alloimmunization, to human leukocyte
Acid-base status, fetal, assessment of, antigens, prevention of, in
517-518 transfusion, 711-713
Acidosis, in hemolytic disease of to platelet antigens, neonatal thrombo-
newborn, 564 cytopenia in, 577-586
Acrosome reaction, of sperm, 414-415 to red cells. See Hemolytic disease of new-
Actin-cytoskeleton, integrin interaction born.
with, 223-224 Allophycocyanin, in flow cytometry, 246
Acute lymphoblastic leukemia, minimal Alpha-fetoprotein, isoforms of, 482
residual cells from, detection of, 139- levels of, in disease, 482-483
145 measurement of, 481-492
Acute myelogenous leukemia, minimal clinical uses of, 483-484
residual cells from, detection of, 145 diabetes mellitus and, 487
Adenosine deaminase deficiency, prenatal drug ingestion and, 487-488
diagnosis of, 513 gestational age and, 486
Adhesion, cellular, integrins in. See _ in amniotic fluid, 488
Integrins. materials for, 484
Adsorption filtration, of transfusion maternal weight and, 486-487
components, for microbial removal, methods for, 484—485
791-792 multiple of median value in, 485-486
Adult T-cell lymphoma-leukemia multiple pregnancy and, 487
syndrome, flow cytometric analysis racial factors in, 487
in, 262 results handling in, 485-489
862 CUMULATIVE INDEX 1992
Alpha-fetoprotein (Continued) Antibody-dependent cell-mediated assay,
physicochemicai properties of, 481 in hemolytic disease of newborn, 562
American Association of Blood Banks, Antibody-dependent cellular cytotoxicity,
legal issues in transfusion and, 819, in HIV infection, 317
822, 825-826, 831 Anticardiolipin antibodies, familial, 43
Aminomethyl trimethyl psoralen in neurologic disease, 75
treatment, of transfusion in recurrent spontaneous miscarriage,
components, 796 407
Amniocentesis, alpha-fetoprotein testing incidence of, 42-43
and, 484, 488-489 Anticoagulant(s), in antiphospholipid
in fetal lung maturity assessment, 603- antibody syndrome, 46-47
630 lupus. See Lupus anticoagulant.
in granulomatous disease detection, 298 Antifibrinolytic agents, in hemostasis, 776
in prenatal diagnosis, 494-495 Antigens. See also specific antigen, e.g.,
efficacy of, 500 p24 antigen.
hemolytic disease of newborn, 559- alloimmunization to, prevention of, in
561 transfusion, 711-713
Tay-Sachs disease, 469 phenotyping of, 765
toxoplasmosis, 508 in HIV infection, 308, 310, 317-318
Amniotic fluid, surfactant in, 606-607 in rheumatic disease, autoantibodies to.
Amplified fragment length See under Autoantibodies.
polymorphisms, in parentage platelet. See Platelet antigens.
analysis, 633 red blood cell. See Blood group markers.
Androgens, assessment of, in infertility to proliferating cells, in cell cycle analy-
evaluation, 398 sis, 179, 190-192
in hemostasis, 776 Antiglobulin test, in antibody screening,
Anemia, aplastic, diagnosis of, molecular 690-692
probe techniques in, 115 in crossmatching, 692-694
hemolytic, in antiphospholipid antibody Antimitochondrial antibodies, in chronic
syndrome, 45 active hepatitis, 33
in newborn. See Hemolytic disease of in primary biliary cirrhosis, 35-36
newborn. Antineutrophil cytoplasmic
transfusion in, 655-656 autoantibodies, 85-98
alternatives to, 658 C-pattern, 85-87
hemoglobin level trigger point and, Wegener's granulomatosis and, 87, 89
656-658 circulating, 92, 94
Angelman syndrome, prenatal diagnosis conditions associated with, 92
of, 498 detection of, 86-87
Antepartum nonstress test, in hemolytic elastase type, 91-92
disease of newborn, 563 historical aspects of, 85-86
Anti-immunoglobulin G reagent, in in primary sclerosing cholangitis, 37-38
antibody screening, for transfusion, in Wegener's granulomatosis, 87, 89
690 lactoferrin type, 91-92
Antibiotic treatment, of transfusion myeloperoxidase recognition by, 85-87,
components, 793-794 89-91, 94
Antibodies. See also Autoantibodies; P (perinuclear/nuclear staining)-pattern,
specific antibody, e.g., 86, 92
Antiphospholipid antibodies. pathogenicity of, 92, 94
antiphospholipid, in recurrent sponta- sensitivity of, 91
neous miscarriage, 407 specificity of, 91
antisperm, detection of, 399-400, 402 Antinuclear antibodies, detection methods
in drug-induced lupus erythematosus, for, 15-16
8-9 in chronic active hepatitis, 26, 29
monoclonal. See Monoclonal antibodies. in recurrent spontaneous miscarriage,
platelet, in transfusion, 663 407
testing for, in transfusion, 687-688, in rheumatic disease, 2
690-692 tests for, 7
to HIV. See under Human immunodefi- Antiphospholipid antibodies, animal
ciency virus. models for, 48
CUMULATIVE INDEX 1992
avidity of, 49 polymyositis, 11-12
binding to phospholipids, 49-50 rheumatoid arthritis, 13-15
characteristics of, 48-51 scleroderma, 12-13
cofactors for, 50-51 Sjégren’s syndrome, 10-11
familial associations of, 43 systemic lupus erythematosus, 2-8,
in neurologic disease, 75-76 76, 90
in recurrent spontaneous miscarriage, to Me autoantigen, 17-18
407 to nuclear lamins, 16-17
incidence of, 42-43 to poly (ADP-ribose) polymerase, 17
isotypes of, 49 in Wegener's granulomatosis, 87, 89
pathogenicity of, 51-52 to neutrophils, 91-92
specificity of, 49-50 Autoimmune disease, antiphospholipid
Antiphospholipid antibody syndrome, 41- antibody syndrome, 41-60
60 of liver, 25-40
historical background of, 41-42 chronic active hepatitis, 26-34
primary, clinical manifestations of, 43- primary biliary cirrhosis, 34-37
46 primary sclerosing cholangitis, 37-38
treatment of, 46-48 Autoimmune disorders, in blood donors,
Antiribossomal P protein, antibodies to, guidelines for, 678
lupus psychosis and, 76 Autoimmune thrombocytopenia, platelet
Antisperm antibodies, detection of, 399- transfusion in, 660-661
400, 402 Autologous transfusion. See under
Antithrombin III, transfusion of, 751-753 Transfusion.
Antiviral drug treatment, of transfusion Automated reagin test, for syphilis, 529
components, 793-794 Automation, in laboratory testing, 851-
Apheresis, components from, uses of, 852
774-775 Autoradiography, in cell cycle analysis,
donor screening for, 681 172-173
platelets from, 663, 774-775 Avitene, in hemostasis, 777
techniques for, 774-775 Azathioprine, in chronic active hepatitis,
Aplastic anemia, diagnosis of, molecular 34
probe techniques in, 115
Aprotinin, in hemostasis, 776-777
Artificial insemination, ethical and lega!
considerations in, 430-436 B-cell lymphoproliferative disorders, after
Autoantibodies. See also specific bone marrow transplantation,
antibody, e.g., Antinuclear antibodies. detection of, 123-124
in chronic active hepatitis, 26-27, 29-33 B-cell prolymphocytic leukemia, flow
in CREST syndrome, 12-13 cytometric analysis in, 260
in Eaton-Lambert syndrome, 77-78 Babesia, in blood transfusion components,
in neurologic disease, 61-83 donor screening for, 676
to antiribossomal P protein, 76 inactivation of, 788
to calcium channel, 77-78 Bacteria, in blood transfusion
to Ki antigen, 77 components, inactivation of. See
to neurofilament, 77 Microbial inactivation.
to neuronal ganglioside antigens, 64— testing for, 763
75 Bak antigens, in neonatal alloimmune
to neuronal proteins, 62-64 thrombocytopenia, 581
to phospholipids, 75-76 Basal body temperature, in ovulation
in primary biliary cirrhosis, 35-36 documentation, 393-395
in primary sclerosing cholangitis, 37-38 Bayes theorem, in paternity inclusion
in rheumatic disease, 1-23 calculation, 629
biological functions of, 18-19 Beckwith-Wiedemann syndrome, prenatal
dermatomyositis, 11-12 diagnosis of, 499
detection methods for, 15-16 Benzoporphyrin derivative treatment, of
drug-induced lupus erythematosus, transfusion components, 797
8-9 Bernard-Soulier syndrome, neonatal
mixed connective tissue disease, 9-10 alloimmune thrombocytopenia and,
of rare occurrence, 16-17 581
864 CUMULATIVE INDEX 1992
Beta-hexosaminidase A deficiency, in Tay- chronic myelogenous leukemia, 133-
Sachs disease, 465, 467-470 139
Beta-propriolactone treatment, of hybridization assay in, 130-131, 137
transfusion components, 795 immunoglobulin rearrangements, 144
Biliary cirrhosis, primary, 34-37 immunophenotyping in, 130
Bilirubin, in amniotic fluid, in hemolytic in autologous marrow, 115-116, 146
disease of newborn, 559-561 lymphoma, 146
Biohazardous waste disposal, regulations polymerase chain reaction in, 131-
on, 841 133, 135-145
Blastomycosis, prenatal diagnosis of, 544— Southern blot in, 130, 135
545 T-cell receptor rearrangements, 144-
Blood, fetal, disorders of, diagnosis of, 145
512-517 molecular probe techniques in, 113-128
sampling of, 495. See also Cordocen- for engraftment documentation, 119-
tesis. 121
lysis of, for flow cytometry, 266-268 for hemopoietic reconstitution clonal-
shipment of, regulations on, 841 ity determination, 121-122
storage of, before transfusion, 706 for histocompatibility typing, 116-119
transfusion of. See Transfusion. for immunodeficiency evaluation, 122
Blood banks, liability of. See Legal issues, for infection diagnosis, 122-123
in transfusion medicine. for pretransplant disease identifica-
regulation of. See Regulatory and legisla- tion, 114-116
tive issues, in transfusion medicine. for secondary malignancies detection,
Blood-borne Pathogen Standard, 840-841 123-124
Blood components, transfusion of. See minisatellite type, 120
Transfusion. Borreliosis, prenatal diagnosis of, 524-525
Blood donors, safety for, 678-680 Bovine cervical mucus penetration test,
screening of, 669-683 403
confidential unit exclusion and, 673- Br antigens, in neonatal alloimmune
675, 703 thrombocytopenia, 581
donor education in, 670-671 Breast cancer, paraneoplastic syndrome
for apheresis, 681 in, autoantibodies in, 63-64
for donor safety, 678-680 Bromodeoxyuridine incorporation
for infectious diseases, 675-676, 701- method, in cell cycle analysis, 179,
703 190
for red cell antibodies, 687-688
goals of, 669
in autologous donation, 680
in directed donation, 681 Calcium channels, antibodies to, in
medical history in, 672-673, 677-678 neurologic disease, 77-78
medication use and, 677 Canadian Association of Pathologists,
national donor referral registry and, workload recording method of, 339-
341
681-682
vaccination and, 676-677 Cancer, cell proliferation markers in. See
Blood group markers, hemolytic disease Cell proliferation markers.
of newborn and, 556-559 immunotherapy in, monoclonal anti-
in linkage analysis, 454-455 bodies in. See under Monoclonal
in parentage analysis, 621-625 antibodies.
Blood protein polymorphisms, in in blood donors, guidelines for, 677-678
parentage analysis, 625-627 integrins role in, 220-222
Blood shield statutes, 820-821 paraneoplastic syndromes in, autoanti-
Bone marrow transplantation, graft- bodies in, 62-64, 77-78
versus-host disease in, 749-751 recurrence of, from transfusion immu-
minimal residual disease detection in, nosuppression, 717, 724-726
129-150, 764-765 secondary, in bone marrow transplanta-
acute lymphoblastic leukemia, 139- tion, detection of, 123-124
143 Candidiasis, prenatal diagnosis of, 544
acute myelogenous leukemia, 145 Capacitation, of sperm, 413-414
CUMULATIVE INDEX 1992 865
Carcinogenesis, cell proliferation markers monoclonal antibody-drug conjugates
and, 164-168 (chemoimmunoconjugates) in, 207-
Carcinoma, in blood donors, guidelines 210
for, 678 Chicken pox, prenatal diagnosis of, 511
Cardiac disease, in antiphospholipid Chimerism, in bone marrow
antibody syndrome, 46 transplantation, 119-121
cDNA sequencing, in granulomatous Chlamydial infections, diagnosis of, in
disease, 297 infertility evaluation, 398-399, 402
Cell(s), adhesion of, integrins in. See in recurrent spontaneous miscarriage,
Integrins. 405
differentiation of, integrins in, 222-223 prenatal, 538
fixation of, for flow cytometry, 273 Cholangitis, primary sclerosing, 37-38
labeling of, for flow cytometry, 269-273 Chorionic villus sampling, 494
signal transduction pathways of, inte- efficacy of, 500
grin interaction with, 224-226 in granulomatous disease detection, 298
Cell counters, in fetal lung maturity in hemolytic disease of newborn, 564
Chromatography, high-pressure liquid,
assessment, 615-617
Cell cycle, cell proliferation markers and, for neopterin, 102-103
169-180 thin-layer, in antiganglioside antibody
detection, 74
phases of, 169-171
in fetal lung maturity assessment,
quantitative measurement of, 171-180
609-611
Cell proliferation antigens. See
Proliferating cell antigens. Chromosomal analysis, in recurrent
spontaneous miscarriage, 406
Cell proliferation markers, 163-199
prenatal, 497-499
carcinogenesis and, 164-168
cordocentesis in, 505-507
cell cycle and, 169-180
Chromosome jumping, in linkage
clinical significance of, 180-192
analysis, 455
growth kinetics and, 168-169 Chromosome walking, in linkage analysis,
measurement of, antigen analysis in, 455
190-192
Chronic inflammatory demyelinating
flow cytometry in, 186-190
polyneuropathy, plasmapheresis in,
halogenated pyrimidine incorporation 600
in, 190 Chronic lymphocytic leukemia, flow
nuclear organizer region technique in, cytometric analysis in, 258, 260
192 Chronic myelogenous leukemia, minimal
metastasis and, 166-168, 182-184 residual cells from, detection of, 133-
prognostic implications of, 180-182, 139
186-190 Cirrhosis, primary biliary, 34-37
therapeutic implications of, 184-186 Clinical Laboratory Improvement
tumor biology and, 164-169 Amendments of 1988, 839-840, 850-
tumor heterogeneity and, 168 851
Centromere antigens, antibodies to, in Clonal deletion theory, of immunosup-
scleroderma, 13 pression, in transfusion, 730
Cerebellar degeneration, paraneoplastic, Clonality, in bone marrow
autoantibodies in, 62-63 transplantation, molecular probe
Cerebrospinal fluid testing, in determination of, 121-122
coccidioidomycosis, 545 Clustering, in test selection, 363-370
Cervical mucus penetration test, 403 Coagulopathy, antithrombin III
Chagas’ disease, transmission of, in replacement in, 751-753
transfusion, 763 cryoprecipitate transfusion in, 665, 772
blood donor screening for, 676 diagnosis of, 764-765
Chemical inactivation, of pathogens, in dilutional, plasma transfusion in, 663-
transfusion components, 793 664
Chemiluminescence assay, monocyte- in massive transfusion, 745, 748
mediated, in hemolytic disease of plasma transfusion in, 664, 772-773
newborn, 562 prenatal diagnosis of, 512-513
Chemotherapy, cell proliferation markers preoperative evaluation of, transfusion
in, 184-186 therapy and, 773-774
866 CUMULATIVE INDEX 1992
Coccidioidomycosis, prenatal diagnosis of, of embryo, in assisted reproduction,
545-546 421, 430-431
Collagen, microfibrillar, in hemostasis, Cryptococcosis, prenatal diagnosis of, 546
777 Culture, of Blastomyces dermatitidis, 544—-
College of American Pathologists, 545
proficiency testing programs of, 850- of Borrelia burgdorferi, 524
851 of chlamydia, 538
workload recording method of. See of embryos, for in vitro fertilization,
Workload recording method. 421-424
Combined immunodeficiency, prenatal of enteroviruses, 536
diagnosis of, 513-514 of herpes simplex virus, 535
Compatibility testing, in transfusion. See of HIV, 318-319, 533
Red cells, transfusion of, safety in. of Listeria monocytogenes, 526
Complement fixation test, in of microorganisms, in infertility evalua-
coccidioidomycosis, 545 tion, 398-399
in toxoplasmosis, 541-542 of Mycobacterium tuberculosis, 527
in trypanosomiasis, 543 of Mycoplasma hominis, 529
Confidential unit exclusion, in blood of Neisseria gonorrhoeae, 528
donation, 673-675, 703 of rubella virus, 534
Congenital disease. See also Genetic of streptococci, 525-526
disease. of Ureaplasma urealyticum, 529
markers for, alpha-fetoprotein as, 481- of varicella-zoster virus, 536-537
492 Cystic fibrosis, linkage analysis in, 458-
prenatal diagnosis of, cordocentesis in. 459
See Cordocentesis. Cytapheresis, in pregnancy, 593-594
Congenital varicella syndrome, 536 Cytochrome P-450 antibodies, in chronic
Connective tissue disease, mixed, active hepatitis, 30-32
autoantibodies in, 9-10 Cytogenetics, prenatal, 496
Cordocentesis, 503-522 cordocentesis in, 505-507
complications of, 504-505 efficacy of, 500-501
diagnostic uses of, acid-base balance fetal cells in maternal blood, 496
evaluation, 517-518 in chromosomal abnormality detec-
chromosomal analysis, 505-507 tion, 497-500
congenital infection identification, indications for, 496-497
507-512 sample collection for, 494-495
hematologic disorders, 512-517 Cytomegalovirus infection, prenatal
hemolytic disease of newborn, 563- diagnosis of, 510, 531-532
564 transmission in transfusion, reduction
metabolic status assessment, 517-518 of, 713-714, 763
historical review of, 503 to neonates, 747
methodology for, 503-504 viral inactivation and, 788
Corticosteroids, in chronic active Cytophilic antibody, in flow cytometry, of
hepatitis, 34 lymphocyte markers, 262
Counseling, linkage analysis and, 458-460 Cytosolic components, autoantibodies
Coupling, in linkage analysis, 450 against, in chronic active hepatitis,
Coxsackievirus infections, prenatal 32-33
diagnosis of, 536
CREST syndrome, autoantibodies in, 12-
13
Creutzfeldt-Jakob disease, screening for, D antigens, determination of, for
in blood donors, 676 transfusion, 686-687, 689
Crohn’s disease, transfusion in, Danazol, in hemostasis, 776
immunosuppression in, 727-728 Data collection, for test selection, 356
Crossmatching, in transfusion, 692-694 in workload recording method, 344-345
Cryoprecipitate, transfusion of, 665 Data organization, for test selection. See
guidelines for, 772 Test selection.
Cryopreservation, for flow cytometry, DDAVP (desmopressin), in hemostasis,
268-269 775
CUMULATIVE INDEX 1992 867
3-Deamino-3-(4-morpholinyl)- Doppler analysis, in hemolytic disease of
doxorubicin-monoclonal antibody newborn, 563
conjugate, in cancer immunotherapy, Down syndrome, markers for, 489-490
208-209 Drug(s), alpha-fetoprotein results and,
1-Deamino-8D-arginine (DDAVP), in 487-488
hemostasis, 775 exclusion of, from donated blood, 677
Decision making, for test selection. See lupus erythematosus induced by, anti-
Test selection. bodies in, 8-9
Dehydroepiandrosterone sulfate, monoclonal antibody-drug conjugates
assessment of, in infertility with, 207-210
evaluation, 398 Duffy antigens, in hemolytic disease of
Dendrograms, in test selection, 361 newborn, 557
Dermatomyositis, autoantibodies in, 11- in parentage analysis, 623
12 Dyes, DNA-specific, in cell cycle analysis,
4-Desacetylvinblastine-3- 173-179
carboxyhydrazide-monoclonal
antibody conjugate, in cancer
immunotherapy, 209-210
Desmopressin, in hemostasis, 775 Early antigen of Epstein-Barr virus,
Detergent treatment, of transfusion antibodies to, in rheumatoid arthritis,
components, 798 14
Diabetes mellitus, alpha-fetoprotein Eaton-Lambert syndrome, autoantibodies
results and, 487 in, 77-78
DiGeorge syndrome, prenatal diagnosis Effector cells, in immunotherapy,
of, 456, 498 activation of, 202-205
Direct antiglobulin test, in hemolytic redirection to tumor sites, 205-207
disease of newborn, 556 Elastase, antineutrophil cytoplasmic
Direct sequencing, of DNA, in parentage autoantibodies to, 91-92
analysis, 634 Electrolytes, in embryo culture media, 423
Directed donation, of blood, transfusion Electron microscopy, pseudoreplica
of, 681, 780 method of, in cytomegalovirus
Disintegrins, 230 detection, 531
DNA, denatured, antibodies to, in drug- Electrophoresis, in hexosaminidase A
induced lupus erythematosus, 8-9 detection, 468
halogenated pyrimidine incorporation in parentage analysis, 625-627
into, in cell cycle analysis, 179 ELISA. See Enzyme-linked immunosorbent
identification of, in HIV, 319-320 assay.
native, antibodies to, in SLE, 2-3 Embryo, development of, integrins in,
nucleolar organizer regions of, in cell 222-223
proliferation measurement, 179- for assisted reproduction, cryopreserva-
180, 192 tion of, 430-431
quantitation in cell cycle analysis, 173- culture of, 421-424
180 ethical and legal status of, 441-445
clinical significance of, 180-192 handling of, 415-421
DNA hybridization, in bone marrow Encephalomyelitis, paraneoplastic,
minimal residual disease, 130-131, autoantibodies in, 64
137 Endometrial biopsy, in infertility
in HIV testing, 319-320 evaluation, 396-397
DNA index, in cell cycle analysis, 174-176 in recurrent spontaneous miscarriage,
DNA ploidy. See Ploidy. 406-407
DNA probes, in malaria diagnosis, 542 Endometrial carcinoma stage I prognostic
DNA-specific dyes, in cell cycle analysis, index, 189
173-179 Endothelial cells, antibodies to, 51-52
DNA studies, in parentage analysis, 630- integrins associated with, 219
636 Enterovirus infections, prenatal diagnosis
DNA topoisomerase II, antibodies to, in of, 535-536
rheumatic disease, 17-18 Environmental Protection Agency,
Donors, blood. See Blood donors. medical waste regulation by, 841
868 CUMULATIVE INDEX 1992
Enzyme analysis, in phosphatidylglycerol Ethical and legal considerations, in
determination, 611 assisted reproduction, 429-448
in Tay-Sachs disease diagnosis, 469 exploitation and, 439-442
Enzyme immunoassay, for alpha- extrauterine embryo status, 442-445
fetoprotein, 484-485 nuclear family fate and, 432-439
for luteinizing hormone surge assess- in Tay-Sachs screening, 476-477
ment, 395 Ethidium bromide, in cell cycle analysis,
in autoantibody detection, 15-16 174
in chlamydial infections, 538 Exclusion filtration, of transfusion
in cryptococcosis, 546 components, for microbial removal,
in gonorrhea, 528 791
in hepatitis B, 538
in HIV infection, 532
in streptococcal infections, 526
Enzyme-linked immunosorbent assay, for Factor VIII, transfusion of, 665
hormones, in infertility evaluation, Family law, in assisted reproduction. See
397 under Ethical and legal considerations.
for infectious organisms, Borrelia burg- FDA (Food and Drug Administration),
dorferi, 524 transfusion medicine regulation by,
in infertility evaluation, 397 836-838
Listeria monocytogenes, 526 Fertilization, in vitro. See In vitro
Toxoplasma gondii, 508, 540-541 fertilization.
Treponema pallidum, 530 Fetus, alloimmune thrombocytopenia
in antiganglioside antibody detection, deveiopment in, 577-586
73-74 alpha-fetoprotein levels in. See Alpha-
in antineutrophil cytoplasmic autoanti- fetoprotein.
body detection, 86-87 cells of, in maternal blood, 496
in autoantibody detection, 15-16 diagnosis of disorders in, blastomy-
in HIV testing, 311-314, 317-318 cosis, 544—545
in interleukin—2 soluble receptor analy- blood disorders, 512-517. See also
sis, 104 Hemolytic disease of newborn.
Epidermal growth factor receptors, in blood sampling for, 495. See also Cor-
tumor, monoclonal antibodies docentesis.
directed to, 210-211 candidiasis, 544
Epithelial cells, integrins associated with, chlamydial infection, 538
218-220 coccidioidomycosis, 545-546
Epstein-Barr virus, detection of, after cryptococcosis, 546
bone marrow transplantation, 123 cytomegalovirus infection, 510,
in blood transfusion components, 763 532
rheumatoid arthritis and, 14 enterovirus infections, 535-536
transmission in transfusion, reduction gonorrhea, 527-528
of, 714-715 hepatitis B, 537-538
Error reports, in transfusion medicine, 837 herpes simplex virus infection, 534-
Erythema infectiosum (parvovirus B19 535
infection), in blood transfusion HIV infection, 532-533
components, testing for, 763 hydrops, 516-517
prenatal diagnosis of, 511-512, 537 infections, 523-552
Erythrocytes. See Red cells. listeriosis, 526-527
Erythroderma, postoperative, in graft- Lyme disease, 524-525
versus-host disease, 749 malaria, 542
Erythropoietin, as transfusion alternative, mycoplasmal infections, 528-529
658, 777-778 papillomavirus infection, 538-539
in *:emolytic disease of newborn, 564- parvovirus B19 infection, 511-512,
565 537
Estradiol, assessment of, in infertility rubella, 510-511, 533-534
evaluation, 398 streptococcal infections, 525-526
Estriol, unconjugated, in Down syndrome syphilis, 529-530
screening, 489-490 Tay-Sachs disease, 468-469
Estrogens, in hemostasis, 776 toxoplasmosis, 507-510, 539-542
CUMULATIVE INDEX 1992 869
trypanosomiasis, 543 in proliferating-cell antigen analysis,
tuberculosis, 527 190-192
varicella-zoster virus infection, 511, Fluorescein, in flow cytometry, 245, 263-
536-537 264
lung maturity assessment in, 603-630 Fluorescence, depolarization of, in fetal
parentage analysis of, 636 lung maturity assessment, 615-616
transfusion for, in alloimmune throm- Fluorescent treponemal antibody
bocytopenia, 584 absorption test, for syphilis, 529-530
in hemolytic disease of newborn, Fluorochromes, in cell cycle analysis, 173-
566-568 179
Feulgen staining technique, in static in flow cytometry, of lymphocyte mark-
cytophotometry, 178 ers, 245-246, 271-273
Fibrillarin, antibodies to, in scleroderma, Foam-stability assay, in fetal lung
13 maturity assessment, 614-615
Fibrin surgical adhesive, in hemostasis, Follicle-stimulating hormone, assessment
777 of, in infertility evaluation, 398, 402
Fibrinogen, integrin recognition of, 226- Follicular center cell lymphoma, flow
227, 229 cytometric analysis in, 260
transfusion of, 665 Food and Drug Administration,
Fibronectin, integrin recognition of, 226- transfusion medicine regulation by,
227 836-838
Ficoll-Hypaque technique, 268 Fragile X syndrome, prenatal diagnosis of,
Fifth disease (parvovirus B19 infection), in 499
blood transfusion components, 763 Fungal infections. See specific infection.
prenatal diagnosis of, 511-512, 537 Fy antigens, in hemolytic disease of
Filtration, of transfusion components, for newborn, 557
microbial removal, 791-792
Flow cytometry, in cell cycle analysis,
174-177, 186-190
in HIV testing, 318 Gamete intrafallopian transfer, ethical and
in lymphocyte marker analysis, 237-275 legal considerations in, 430-432
antibody labeling techniques in, 263- Gamma globulin, in neonatal alloimmune
266 thrombocytopenia, 584-585
biohazards precautions in, 274 in plasmapheresis, 599
cell fixation for, 273 Gamma irradiation, of transfusion
cell gating settings for, 243-244 components, for microbial
cell labeling for, 269-273 inactivation, 794-795
compensation settings for, 241, 243 in graft-versus-host disease preven-
computer data acquisition in, 239 tion, 750-751
fluorochromes for, 245-246, 271-273 Gangliosides, 64-75
in B-cell prolymphocytic leukemia, antibodies to, detection of, 72-75
260 diseases associated with, 70
in chronic lymphocytic leukemia, 258, mechanism of action of, 72
260 origin of, 71-72
in follicular center cell lymphoma, 260 pathogenicity of, 71
in hairy cell leukemia, 260 specificity of, 70-71
in plasmacytoid lymphocytic lym- characteristics of, 70
phoma, 260 molecular structure of, 65
in T-cell chronic lymphoproliferative tissue localization of, 65, 70
disease, 260, 262 Gene-dosage methods, in linkage
instrumentation for, 238-245 analysis, 455-456
monoclonal antibodies for, 246-247 Gene mapping. See under Liiikage analysis.
procedure for, 263-274 Genetic disease. See also Congenital
quality control in, 244-245, 273-274 disease.
results interpretation in, 247, 255-263 diagnosis of, 493-502
settings in, 239-244 alpha-fetoprotein markers in, 481-492
specimen handling in, 266-269 chromosomal syndromes, 497-499
technical problems in, 262-263 efficacy of methods for, 500-501
voltage gain settings for, 239-241 genomic imprinting and, 499-500
870 CUMULATIVE INDEX 1992
Genetic disease (Continued) testing in, CDNA sequencing, 297
in assisted reproductive technology, NADPH oxidase component gene
495 characterization, 293, 295
indications for, 496-497 Northern analysis, 296
overview of, 493-494 polymerase chain reaction, 297
preconceptive, 495-496 prer.atal, 297-299
techniques for, 494-495, 500-501 Southern analysis, 296
with fetal cells in maternal blood, 496 Growth factors, hematopoietic, as
prediction of, linkage analysis in, 449- transfusion alternatives, 777-778
462 receptors for, in tumor, monoclonal an-
counseling in, 458-460 tibodies directed to, 210-211
definitions in, 450 Guillain-Barré syndrome, in blood donors,
gene mapping methods in, 450-458 guidelines for, 678
Human Genome Initiative project, plasmapheresis in, 599-600
460
Tay-Sachs disease, 463-480
recurrent spontaneous miscarriage and,
406 Hairy cell leukemia, flow cytometric
Gestational age, alpha-fetoprotein results analysis in, 260
and, 486 Halogenated pyrimidine incorporation
GIFT (gamete intrafallopian transfer), method, in cell cycle analysis, 179,
ethical and legal considerations in, 190
430-432
Hamster test (sperm penetration assay),
Glioblastoma multiforme, integrins in, 402-403
220-221 Hazardous waste disposal, regulations on,
Glioma, immunotherapy in, monoclonal 841
antibodies in, 209-210 Health Care Financing Administration,
Glucose, in embryo culture media, 423 transfusion medicine regulation by,
Glucose—6-phosphate dehydrogenase 838-840
deficiency, defective respiratory burst Heart, transplantation of, rejection
in, 284-285 markers in, 106, 108-109
Glue, fibrin, in hemostasis, 777
Heat shock protein 90, antibodies to, in
Glutathione reductase deficiency,
rheumatic disease, 6
defective respiratory burst in, 285
Heat treatment, of transfusion
GM, ganglioside, in Tay-Sachs disease,
components, for microbial
466-467
inactivation, 791
Gonorrhea, prenatal diagnosis of, 527-528
Hemagglutination test, in syphilis, 529-
Goodpasture’s syndrome, plasmapheresis
530
in, 600
in toxoplasmosis, 541
Graft-versus-host disease, in transfusion,
Hemapheresis. See also Plasmapheresis.
718, 749-751
Granulocyte-macrophage colony- in pregnancy, 587-602
in dermatologic disease, 601
stimulating factor, in cancer
in gastrointestinal disease, 601
immunotherapy, 205
Granulocyte-monocyte colony stimulation in hematologic disease, 593-598
factor, as transfusion alternative, 778 in neurologic disorders, 599-600
Granulomatous disease, 277-305 in renal disease, 600
autoantibodies in, 87, 89 in rheumatologic disease, 600
carrier state of, diagnosis of, 292-293 indications for, 587
classification of, 280-281, 284, 292, 294 machine (centrifugal), 588
clinical features of, 289, 292-293 manual, 588
incidence of, 280 nontreatment, 592-593
infections in, 288-289, 292 replacement solutions for, 598-599
pathogenesis of, 280-288 technique for, 592
phagocyte respiratory burst and, defec- technology for, 587-588
tive, 280-288 therapeutic, 593-601
normal, 277-280 volume calculations for, 588-592
regulation of, 279-280 Hematocrit, extremely low, death in, 656
prenatal diagnosis of, 513-514 Hematologic disorders. See under Blood.